Actavis's Viberzi gets FDA approval to treat IBS-D

The US Food and Drug Administration (FDA) has granted approval for Actavis's Viberzi (eluxadoline) as a twice-daily and oral treatment for adults suffering from irritable bowel syndrome with diarrhoea (IBS-D).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news